Bowel cancer is the fourth most common cancer in the UK with nearly 43,000 people diagnosed every year.
“Our understanding of the biology of bowel cancer is really advancing very rapidly, and this has been helped by the ability to examine samples of tumours with a wide range of molecular tools,” explains Simon Leedham, Professor of Molecular and Population Genetics from the University of Oxford, and Honorary Consultant at the John Radcliffe Hospital.
Funding from Cancer Research UK has enabled the Leedham Lab NDM at Oxford University to develop a brand-new molecular tool, which could lead to a step change in how to choose the best treatment for each patient at the right time.